From Wikipedia, the free encyclopedia
  (Redirected from Virosomes)
Jump to: navigation, search

A virosome is a drug or vaccine delivery mechanism consisting of unilamellar phospholipid membrane (either a mono- or bi-layer) vesicle incorporating virus derived proteins to allow the virosomes to fuse with target cells. Virosomes are not able to replicate but are pure fusion-active vesicles.

Influenza virosomes[edit]

In contrast to liposomes, virosomes contain functional viral envelope glycoproteins: influenza virus hemagglutinin (HA) and neuraminidase (NA) intercalated in the phospholipid bilayer membrane. They have a typical mean diameter of 150 nm. Essentially, virosomes represent reconstituted empty influenza virus envelopes, devoid of the nucleocapsid including the genetic material of the source virus.[1]

The unique properties of virosomes partially relate to the presence of biologically active influenza HA in their membrane. This viral protein not only confers structural stability and homogeneity to virosome-based formulations, but it significantly contributes to the immunological properties of virosomes, which are clearly distinct from other liposomal and proteoliposomal carrier systems. It has been shown that a physical association between the virosome and the antigen of interest is necessary for the full adjuvant effect of virosomes.[citation needed] Such physical association can be achieved by a variety of methods, depending on the properties of the antigen. Antigens can be incorporated into virosomes, adsorbed to the virosome surface, or integrated into the lipid membrane, either via hydrophobic domains or lipid moieties cross-linked to the antigen.

Virosomes therefore represent an innovative, broadly applicable adjuvant and carrier system with prospective applications in areas beyond conventional vaccines. They are one of only three adjuvant systems widely approved by regulatory authorities[citation needed] and the only one that has carrier capabilities.[citation needed]

Non-influenza virosomes[edit]

They are also being considered for HIV-1 vaccine research.[2]

They were used as a drug carrier mechanism for experimental cancer therapies.[3]


  1. ^ hHuckriede, Anke; Bungener, Laura; Stegmann, Toon; Daemen, Toos; Medema, Jeroen; Palache, Abraham M.; Wilschut, Jan (2005). "The virosome concept for influenza vaccines". Vaccine. 23: S26–38. PMID 16026906. doi:10.1016/j.vaccine.2005.04.026. 
  2. ^ HIV VIROSOMES.[full citation needed]
  3. ^ Waelti, Ernst; Wegmann, Nina; Schwaninger, Ruth; Wetterwald, Antionette; Wingenfeld, Carsten; Rothen-Rutishauser, Barbara; Gimmi, Claude D. (2002). "Targeting her-2/neu with antirat Neu virosomes for cancer therapy". Cancer Research. 62 (2): 437–44. PMID 11809693.